+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
MALE
ID07686016

Observational Registry on Outcomes After Definitive Prostate and Metastasis-Directed Radiotherapy for Men with Synchronous Oligometastatic Prostate Cancer

Led by Affidea Nu-med Center of Oncological DIagnostics and Therapy · Updated on 2026-07-06

700

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting an ambispective, multicenter, observational real-world registry to study men with synchronous de novo oligometastatic prostate cancer, defined as having up to 10 metastatic lesions outside the prostate diagnosed at initial presentation or within six months of the primary diagnosis. The purpose is to evaluate outcomes after comprehensive local and metastasis-directed radiotherapy treatments without assigning specific therapies or imaging schedules. This study aims to understand where and when cancer progresses following combined treatments and to identify factors linked to disease control and side effects. Participants receive definitive prostate-directed radiotherapy, which may include external-beam radiotherapy, brachytherapy boost, or prostate brachytherapy monotherapy, alongside stereotactic body radiotherapy targeting all visible metastatic lesions. Pelvic lymph node irradiation may also be used per institutional standards. Systemic therapies, such as androgen deprivation or chemotherapy, are administered according to routine clinical practice and recorded but not assigned by the study. The registry includes retrospective data from previously treated patients, prospective follow-up of ongoing patients, and prospective enrollment of newly eligible patients. Participants data are collected from routine medical records, including imaging, treatment details, systemic therapies, progression, adverse events, and survival. The study measures time to first radiographic progression, patterns of failure, time to further progression, next systemic therapy initiation, overall survival, and treatment-related adverse events. Data are de-identified and centrally recorded, with analyses focusing on descriptive and exploratory outcomes to improve understanding of treatment effects in this patient group.

CONDITIONS

Brief Title

Prostate Radiotherapy and Metastasis-Directed Therapy in Synchronous Oligometastatic Prostate Cancer

Research Team

M

Mateusz Bilski, MD, PhD

P

Paulina Kleban

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here